Role of metabolic dysfunction in treatment resistance of major depressive disorder

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Major depressive disorder (MDD) and metabolic syndrome (MetS) are both widespread and cause enormous morbidity. The presence of one syndrome approximately doubles the risk of the other. Standard antidepressant treatments lead to remission in less than a third of the patients; a majority of patients experience treatment resistance at some point during their illness. Research focusing on clinical and biological markers has yet to provide evidence for the cause(s) of treatment resistance. MDD and MetS share endocrine and immune abnormalities that account for their overlap and suggest potential mechanisms for treatment resistance for a subgroup of patients with MDD. Cortisol resistance and positive energy balance work together to create inflammation. Chronic inflammation leads to insulin resistance. In the brain, inflammation and insulin resistance cause changes in metabolic control, decreases in serotonin synthesis, decreased hedonic drive and lower hippocampal neurogenesis, all of which are consistent with the neurobiology of MDD. We hypothesize that treatment-resistant MDD may result when MetS reinforces the pathophysiology of MDD, making it harder to reverse.

Original languageEnglish (US)
Pages (from-to)441-455
Number of pages15
JournalNeuropsychiatry
Volume1
Issue number5
DOIs
StatePublished - Oct 2011

Fingerprint

Major Depressive Disorder
Inflammation
Insulin Resistance
Therapeutics
Biomarkers
Treatment-Resistant Depressive Disorder
Pleasure
Neurobiology
Neurogenesis
Antidepressive Agents
Hydrocortisone
Serotonin
Morbidity
Brain
Research

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Role of metabolic dysfunction in treatment resistance of major depressive disorder. / Toups, Marisa S.; Trivedi, Madhukar H.

In: Neuropsychiatry, Vol. 1, No. 5, 10.2011, p. 441-455.

Research output: Contribution to journalArticle

@article{e50fffb607a44060be70d044ad60ae2c,
title = "Role of metabolic dysfunction in treatment resistance of major depressive disorder",
abstract = "Major depressive disorder (MDD) and metabolic syndrome (MetS) are both widespread and cause enormous morbidity. The presence of one syndrome approximately doubles the risk of the other. Standard antidepressant treatments lead to remission in less than a third of the patients; a majority of patients experience treatment resistance at some point during their illness. Research focusing on clinical and biological markers has yet to provide evidence for the cause(s) of treatment resistance. MDD and MetS share endocrine and immune abnormalities that account for their overlap and suggest potential mechanisms for treatment resistance for a subgroup of patients with MDD. Cortisol resistance and positive energy balance work together to create inflammation. Chronic inflammation leads to insulin resistance. In the brain, inflammation and insulin resistance cause changes in metabolic control, decreases in serotonin synthesis, decreased hedonic drive and lower hippocampal neurogenesis, all of which are consistent with the neurobiology of MDD. We hypothesize that treatment-resistant MDD may result when MetS reinforces the pathophysiology of MDD, making it harder to reverse.",
author = "Toups, {Marisa S.} and Trivedi, {Madhukar H.}",
year = "2011",
month = "10",
doi = "10.2217/npy.11.49",
language = "English (US)",
volume = "1",
pages = "441--455",
journal = "Neuropsychiatry",
issn = "1758-2008",
publisher = "University of Virginia",
number = "5",

}

TY - JOUR

T1 - Role of metabolic dysfunction in treatment resistance of major depressive disorder

AU - Toups, Marisa S.

AU - Trivedi, Madhukar H.

PY - 2011/10

Y1 - 2011/10

N2 - Major depressive disorder (MDD) and metabolic syndrome (MetS) are both widespread and cause enormous morbidity. The presence of one syndrome approximately doubles the risk of the other. Standard antidepressant treatments lead to remission in less than a third of the patients; a majority of patients experience treatment resistance at some point during their illness. Research focusing on clinical and biological markers has yet to provide evidence for the cause(s) of treatment resistance. MDD and MetS share endocrine and immune abnormalities that account for their overlap and suggest potential mechanisms for treatment resistance for a subgroup of patients with MDD. Cortisol resistance and positive energy balance work together to create inflammation. Chronic inflammation leads to insulin resistance. In the brain, inflammation and insulin resistance cause changes in metabolic control, decreases in serotonin synthesis, decreased hedonic drive and lower hippocampal neurogenesis, all of which are consistent with the neurobiology of MDD. We hypothesize that treatment-resistant MDD may result when MetS reinforces the pathophysiology of MDD, making it harder to reverse.

AB - Major depressive disorder (MDD) and metabolic syndrome (MetS) are both widespread and cause enormous morbidity. The presence of one syndrome approximately doubles the risk of the other. Standard antidepressant treatments lead to remission in less than a third of the patients; a majority of patients experience treatment resistance at some point during their illness. Research focusing on clinical and biological markers has yet to provide evidence for the cause(s) of treatment resistance. MDD and MetS share endocrine and immune abnormalities that account for their overlap and suggest potential mechanisms for treatment resistance for a subgroup of patients with MDD. Cortisol resistance and positive energy balance work together to create inflammation. Chronic inflammation leads to insulin resistance. In the brain, inflammation and insulin resistance cause changes in metabolic control, decreases in serotonin synthesis, decreased hedonic drive and lower hippocampal neurogenesis, all of which are consistent with the neurobiology of MDD. We hypothesize that treatment-resistant MDD may result when MetS reinforces the pathophysiology of MDD, making it harder to reverse.

UR - http://www.scopus.com/inward/record.url?scp=84876511892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876511892&partnerID=8YFLogxK

U2 - 10.2217/npy.11.49

DO - 10.2217/npy.11.49

M3 - Article

AN - SCOPUS:84876511892

VL - 1

SP - 441

EP - 455

JO - Neuropsychiatry

JF - Neuropsychiatry

SN - 1758-2008

IS - 5

ER -